Sydney Uni spinout lands deal to develop psychiatric drugs
Kinoxis Therapeutics has announced a strategic partnership with Boehringer Ingelheim for the development of first-in-class oxytocin-targeting precision psychiatry treatments.
New South Wales Michael Kassiou Michael Bowen School Of Chemistry University Of Sydney Drug Discovery Initiative University Of Sydney
Source: labonline.com.au